CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project focuses on developing a novel hydrogel treatment using Galectin-3 inhibitors for Idiopathic Pulmonary Fibrosis, a severe lung disease. It aims to optimize drug delivery and analyze genetic and glycosylation patterns to enhance understanding of disease mechanisms and improve treatment options.
Idiopathic Pulmonary Fibrosis (IPF) accounts for a progressive pathology with extremely high mortality and no cure available.
There is a need to study pathology mechanisms for efficient treatments development.
Galectin-3 (Gal-3) has shown promising effects in slowing down IPF.
In this project, I will optimise nebulisation of a novel Gal-3 inhibitory drug (TD139) hydrogel treatment in bleomycin-induced PF mice model, perform an exhaustive genomic analysis to assess single-cell RNA trajectories du…
UNIVERSITY OF GALWAY
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
United States, New Haven
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
